"A decade's worth of work in a matter of days": The journey to telehealth for the whole population in Australia.

COVID-19 Health policy Remote consulting Remuneration Telehealth Telemedicine

Journal

International journal of medical informatics
ISSN: 1872-8243
Titre abrégé: Int J Med Inform
Pays: Ireland
ID NLM: 9711057

Informations de publication

Date de publication:
07 2021
Historique:
received: 11 02 2021
revised: 16 04 2021
accepted: 05 05 2021
pubmed: 14 5 2021
medline: 3 6 2021
entrez: 13 5 2021
Statut: ppublish

Résumé

Internationally the COVID-19 pandemic has triggered a dramatic and unprecedented shift in telehealth uptake as a means of protecting healthcare consumers and providers through remote consultation modes. Early in the pandemic, Australia implemented a comprehensive and responsive set of policy measures to support telehealth. Initially targeted at protecting vulnerable individuals, including health professionals, this rapidly expanded to a "whole population" approach as the pandemic evolved. This policy response supported health system capacity and community confidence by protecting patients and healthcare providers; creating opportunities for controlled triage, remote assessment and treatment of mild COVID-19 cases; redeploying quarantined or isolated health care workers (HCWs); and maintaining routine and non-COVID healthcare. This paper provides a review of the literature regarding telephone and video consulting, outlines the pre-COVID background to telehealth implementation in Australia, and describes the national telehealth policy measures instituted in response to COVID-19. Aligned with the existing payment system for out of hospital care, and funded by the national health insurance scheme, a suite of approximately 300 temporary telehealth Medicare-subsidised services were introduced. Response to these initiatives was swift and strong, with 30.01 million services, at a cost of AUD $1.54 billion, claimed in the first six months. This initiative has been a major policy success, ensuring the safety of healthcare consumers and healthcare workers during a time of great uncertainty, and addressing known financial risks and barriers for health service providers. The risks posed by COVID-19 have radically altered the value proposition of telehealth for patients and clinicians, overcoming many previously encountered barriers to implementation, including willingness of clinicians to adopt telehealth, consumer awareness and demand, and the necessity of learning new ways of conducting safe consultations. However, ensuring the quality of telehealth services is a key ongoing concern. Despite a preference by policymakers for video consultation, the majority of telehealth consults in Australia were conducted by telephone. The pronounced dominance of telephone item numbers in early utilisation data suggests there are still barriers to video-consultations, and a number of challenges remain before the well-described benefits of telehealth can be fully realised from this policy and investment. Ongoing exposure to a range of clinical, legislative, insurance, educational, regulatory, and interoperability concerns and solutions, driven by necessity, may drive changes in expectations about what is desirable and feasible - among both patients and clinicians.

Identifiants

pubmed: 33984625
pii: S1386-5056(21)00109-X
doi: 10.1016/j.ijmedinf.2021.104483
pmc: PMC8103781
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

104483

Informations de copyright

Copyright © 2021. Published by Elsevier B.V.

Références

Br J Gen Pract. 2020 May 28;70(695):268-269
pubmed: 32393502
Br J Gen Pract. 2019 Aug 29;69(686):e586-e594
pubmed: 31160368
J Pain Symptom Manage. 2020 Jul;60(1):e12-e14
pubmed: 32240756
J Prim Care Community Health. 2020 Jan-Dec;11:2150132720922957
pubmed: 32340531
Bull World Health Organ. 2012 May 1;90(5):341-347D
pubmed: 22589567
Med J Aust. 2020 Aug;213(3):104-106.e1
pubmed: 32623740
Open Forum Infect Dis. 2019 Apr 20;6(5):ofz196
pubmed: 31139674
J Am Acad Dermatol. 2020 May;82(5):1213-1214
pubmed: 32229278
Turk J Med Sci. 2020 Apr 18;50(SI-1):489-494
pubmed: 32304192
J Med Internet Res. 2018 Apr 17;20(4):e150
pubmed: 29625956
Cochrane Database Syst Rev. 2020 Mar 26;3:CD011942
pubmed: 32216074
JMIR Med Inform. 2019 Dec 3;7(4):e13042
pubmed: 31793888
JMIR Mhealth Uhealth. 2015 Sep 17;3(3):e90
pubmed: 26381104
Med J Aust. 2014 May 19;200(9):530-3
pubmed: 24835716
BMC Health Serv Res. 2016 May 16;16:183
pubmed: 27185041
Br J Gen Pract. 2019 Aug 29;69(686):e595-e604
pubmed: 31262846
Am J Emerg Med. 2021 Jun;44:468-469
pubmed: 32303410
Aust J Prim Health. 2013;19(4):283-6
pubmed: 24134865
N Engl J Med. 2017 Oct 19;377(16):1585-1592
pubmed: 29045204
J Gen Intern Med. 2018 Aug;33(8):1242-1244
pubmed: 29691713
BMJ Open. 2016 Jan 29;6(1):e009388
pubmed: 26826147
Int J Public Health. 2012 Apr;57(2):447-52
pubmed: 21318326
Rural Remote Health. 2016 Oct-Dec;16(4):3808
pubmed: 27744708
Lancet. 2020 Apr 11;395(10231):1180-1181
pubmed: 32278374
J Med Internet Res. 2020 May 11;22(5):e18378
pubmed: 32391799
J Telemed Telecare. 2017 Feb;23(2):301-313
pubmed: 26985004
PLoS One. 2019 Aug 30;14(8):e0221848
pubmed: 31469865
J Clin Virol. 2020 May;126:104345
pubmed: 32278298
Cochrane Database Syst Rev. 2015 Sep 07;(9):CD002098
pubmed: 26343551
Aust Health Rev. 2010 Aug;34(3):276-81
pubmed: 20797357
JMIR Ment Health. 2018 Nov 21;5(4):e62
pubmed: 30463836
JMIR Public Health Surveill. 2020 Apr 7;6(2):e18961
pubmed: 32250963
J Telemed Telecare. 2016 Jul;22(5):296-303
pubmed: 26362562
Stud Health Technol Inform. 2019 Aug 9;265:213-218
pubmed: 31431601
N Engl J Med. 2020 Apr 30;382(18):1679-1681
pubmed: 32160451
BMJ. 2020 Mar 30;368:m1279
pubmed: 32229477
Med J Aust. 2020 Sep;213(5):237-237.e1
pubmed: 32803783
Am J Obstet Gynecol. 2012 Jul;207(1):3-8
pubmed: 22464291
BMJ. 2020 Mar 25;368:m1182
pubmed: 32213507
BMJ Qual Saf. 2016 Nov;25(11):870-880
pubmed: 26543068
J Telemed Telecare. 2020 Jun;26(5):309-313
pubmed: 32196391
J Telemed Telecare. 2012 Mar;18(2):109-14
pubmed: 22267306
Aust J Rural Health. 2017 Jun;25(3):185-186
pubmed: 27076386
NPJ Digit Med. 2020 May 4;3:64
pubmed: 32377575
Aust J Prim Health. 2020 Jun;26(3):207-211
pubmed: 32454003
PLoS One. 2013 Aug 19;8(8):e71238
pubmed: 23977001
J Innov Health Inform. 2018 Mar 15;25(1):14-18
pubmed: 29717950

Auteurs

Sally Hall Dykgraaf (S)

COVID-19 Action Research Team, College of Health & Medicine, Australian National University, Australia. Electronic address: sally.hall@anu.edu.au.

Jane Desborough (J)

COVID-19 Action Research Team, College of Health & Medicine, Australian National University, Australia.

Lucas de Toca (L)

Acting FAS COVID-19 Primary Care Response, Primary Care Division, Australian Government Department of Health, Australia.

Stephanie Davis (S)

Medical Advisory Unit, Primary Care Division, Australian Government Department of Health, Australia.

Leslee Roberts (L)

Medical Advisory Unit, Primary Care Division, Australian Government Department of Health, Australia.

Ashvini Munindradasa (A)

ANU Medical School, Australian National University, Australia.

Alison McMillan (A)

Australian Government Department of Health, Australia.

Paul Kelly (P)

Australian Government Department of Health, Australia.

Michael Kidd (M)

Australian Government Department of Health, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH